Myofibrillogenesis regulator-1 overexpression is associated with poor prognosis of gastric cancer patients

Table 1 Association of myofibrillogenesis regulator-1 protein expression with clinicopathological variables of gastric cancer patients

Variables	Cases	MR-1 negativen = 43 (%)	MR-1 positiven = 27 (%)	P value
Gender				0.855
Male	45	28 (62.22)	17 (37.78)
Female	25	15 (60.00)	10 (40.00)
Location				0.246
Upper	8	3 (37.50)	5 (62.50)
Lower	62	40 (64.52)	22 (35.48)
Age (yr)				0.400
< 55	25	17 (68.00)	8 (32.00)
≥ 55	45	26 (57.78)	19 (42.22)
TNM stage				0.034
I+ II	21	17 (80.95)	4 (19.05)
III + IV	49	26 (53.06)	23 (46.94)
Depth of invasion				0.809
T1 + T2	12	7 (58.33)	5 (41.67)
T3 + T4	58	36 (62.07)	22 (37.93)
Lymph node metastasis				0.347
Negative	12	9 (75.00)	3 (25.00)
Positive	58	34 (58.62)	24 (41.38)
Distant metastasis				0.196
M0	64	41 (64.06)	23 (35.94)
M1	6	2 (33.33)	4 (66.67)
Vascular invasion				0.887
Negative	41	25 (60.98)	16 (39.02)
Positive	27	16 (59.26)	11 (40.74)
Differentiation				0.278
Well and moderately	3	1 (33.33)	2 (66.67)
Poorly	60	36 (60.00)	24 (40.00)
Others	5	4 (80.00)	1 (20.00)

TNM: Tumor node metastasis; MR-1: Myofibrillogenesis regulator-1.